immunitoAI® is an AI-native therapeutics company building antibody drug assets. The disease sets the mechanism of action, the mechanism sets the epitope, and the antibody is designed specifically against it.
immunitoAI® is an AI-native therapeutics company building antibody drug assets. The disease sets the mechanism of action, the mechanism sets the epitope, and the antibody is designed specifically against it.
Our vision is to unleash the full potential of antibody-based biological drugs and make antibody therapy the norm.
AbInitio™, our AI platform, designs novel antibodies against any protein target, with drug properties built into the sequence from the start, because a molecule that binds is not yet a drug. Our biology lab proves the function and selects the molecule that moves forward.
Biology First
The disease sets the blueprint
Epitope and mechanism of action, locked before design begins
Format follows biology: monovalent, multivalent, multi-specific
Even the choice of deep learning model follows the biology
Designed for function — not just binding
Drug First
Designed as drugs from the first sequence — no lead to optimise
First-in-class where none exists, best-in-class where one does
A building block that carries into bispecifics, CAR-T and ADCs
Developability screened before a molecule reaches the lab
Intelligence Driven
AbInitio™: a family of deep learning models, built entirely in-house
Designed de novo, not screened from existing antibodies
Epitope-specific design, any protein target, agonism and antagonism
Our lab decides what advances; results feed back to improve the models
AbInitio™ was built in-house, and so was everything it has produced. No licensed models, no in-licensed assets. See the pipeline →
Foundational AI, developed entirely in-house. The architectures, the training and the biological features they learn from are all ours.
Every molecule in our pipeline was designed on AbInitio™ and proven in our own lab. Wholly owned at every stage.
Every programme generates experimental data in our own lab, unavailable anywhere else. It feeds back into the deep learning models that design the next one.
Our own programmes go to a development candidate. Where a partner's target matters more, we build it with them — and the value still sits in the asset. Talk to us →
Your target, our engine. From antigen structure to functional, developable leads.
We take a programme forward together, from candidate into preclinical.
Out-licensing of our own assets, programme by programme.
Join immunitoAI in our journey of "Making Antibody Therapy the Norm".